Emerging Treatments for HER2-positive Early-stage Breast Cancer: Focus on Neratinib
[OncoTargets and Therapy] This research reviews available data on the role of the HER2 pathway in breast cancer and on the different targeted agents for the treatment of patients with early-stage HER2-positive disease, with a particular focus on neratinib.
